What are the underlying mechanisms of long COVID, and how can they be targeted therapeutically?

The underlying mechanisms of long COVID (post-acute sequelae of SARS-CoV-2 infection, PASC) are multifactorial, involving overlapping biological pathways that contribute to the persistence and diversity of symptoms across organ systems. Recent research increasingly supports that long COVID is not attributable to a single cause but results from the interplay of viral, immunological, vascular, metabolic, and psychological factors. Understanding these mechanisms is essential for targeted therapeutic development.

Underlying Mechanisms of Long COVID

1. Viral Persistence and Antigen Reservoirs

• Mechanism: Persistence of SARS-CoV-2 RNA or antigens in tissues (such as gut, lymphoid tissue, or nervous system) can lead to chronic immune activation and ongoing local or systemic inflammation, even when infectious virus is not detectable in the respiratory tract.
• Evidence: Some studies report detection of viral proteins or RNA months post-infection, supporting a model where incomplete viral clearance perpetuates inflammation and symptoms, particularly in tissues with immune privilege or altered immune surveillance[1][2][3][4].
• Therapeutic Implications: Antiviral agents (e.g., nirmatrelvir/ritonavir, remdesivir) could be trialed to target persistent reservoirs. This approach is under investigation, though robust clinical trial data are lacking[5].

2. Immune Dysregulation and Chronic Inflammation

• Mechanism: Long-lasting activation of innate and adaptive immunity, marked by elevated cytokines (IL-6, TNF-α), monocyte/macrophage activation, and exhausted or aberrant T-cell responses, may drive chronic symptoms and tissue dysfunction[1][6][4][7][8].
• Evidence: Immune activation often continues in the convalescent phase. Elevated markers like kynurenine, a tryptophan catabolite associated with inflammatory responses, are noted in long COVID patients, even when C-reactive protein and other acute markers normalize[7].
• Therapeutic Implications: Immune-modulating drugs—such as corticosteroids, IL-6 inhibitors, or low-dose naltrexone—may help attenuate pathological inflammation. Biomarker-driven stratification could inform personalized anti-inflammatory therapy[8].

3. Autoimmunity

• Mechanism: Molecular mimicry between viral peptides and host antigens may elicit autoantibody generation, potentially targeting multiple tissues and contributing to persistent symptoms or organ-specific autoimmune sequelae[9][10][11].
• Evidence: While numerous autoantibodies have been reported in post-COVID states, recent high-throughput profiling indicates that although autoantibody signatures are altered post-infection, there is no distinct autoantibody pattern reliably distinguishing long COVID from full recovery[12]. Nevertheless, clinical overlap with autoimmune syndromes is observed.
• Therapeutic Implications: For patients displaying clinical or serological evidence of autoimmunity, immunosuppressive therapies such as B-cell depletion (rituximab) may be considered, although further validation in controlled trials is required.

4. Endothelial Dysfunction and Microvascular Injury

• Mechanism: Direct endothelial infection, inflammatory cytokine exposure, and complement activation can result in endotheliopathy, microthrombi, and impaired tissue perfusion[1][13][6]. This injury may underlie persistent symptoms such as fatigue, dyspnea, chest pain, and neurological deficits.
• Evidence: Long-term abnormalities in vascular biomarkers and persistence of procoagulant states have been documented[13]. Microvascular dysfunction may also drive neurocognitive impairment via blood-brain barrier disruption[14].
• Therapeutic Implications: Therapies such as low-dose anticoagulants (aspirin, direct oral anticoagulants) or agents improving endothelial function (statins) are logical candidates for clinical testing in selected patients[13][8].

5. Autonomic Nervous System Dysfunction (Dysautonomia)

• Mechanism: Multiple lines of evidence suggest post-infectious dysregulation of autonomic control, manifesting as postural orthostatic tachycardia syndrome (POTS), orthostatic intolerance, and other forms of dysautonomia[1][15][14][6].
• Evidence: High prevalence of such symptoms is observed in long COVID cohorts[15]. Proposed mechanisms include autoimmunity against adrenergic receptors, persistent low-level inflammation, and direct viral effects on peripheral nerves.
• Therapeutic Implications: Management involves symptomatic therapies (beta-blockers, fludrocortisone, salt/fluid loading), autonomic rehabilitation, and in some cases immune modulation[14][6].

6. Mitochondrial Dysfunction and Metabolic Disturbances

• Mechanism: Inflammatory signaling and direct viral effects can cause mitochondrial injury, resulting in impaired energy metabolism, chronic fatigue, and exercise intolerance[6][8][11].
• Evidence: Metabolic profiling shows disrupted tryptophan metabolism and changes in mitochondrial pathways in long COVID[7].
• Therapeutic Implications: Supportive therapies (CoQ10, NAD+ boosters), nutritional support, and graduated rehabilitation may offer benefit; however, definitive trials are lacking.

7. Neurological and Cognitive Sequelae

• Mechanism: Long COVID is associated with neuroinflammation, possible direct neuroinvasion, microvascular injury, and disturbances in neurotransmitter pathways[15][14][6][8][11]. Sleep disturbances and neuropsychiatric symptoms, such as anxiety and depression, are also prevalent[16][17].
• Evidence: Structural and functional brain changes are documented post-infection[14]. Elevated kynurenine, implicated in neuroinflammation, persists in some patients and may underlie cognitive and psychiatric symptoms[7].
• Therapeutic Implications: Treatment is currently symptomatic: cognitive rehabilitation, neuromodulatory medications, psychotropics, and sleep hygiene interventions. Research into anti-neuroinflammatory agents and neuroprotective strategies is ongoing[15][14][8].

8. Reactivation of Latent Viruses

• Mechanism: SARS-CoV-2-induced immune dysregulation can allow reactivation of latent viruses (e.g., EBV, HHV-6, CMV), further contributing to systemic symptoms and perhaps perpetuating immune activation[2][9][10].
• Evidence: Increased reactivation markers (elevated EBV titers) are identified in subsets of long COVID patients[9].
• Therapeutic Implications: Antiviral therapies directed at reactivating viruses and immune fortification could be explored in targeted clinical trials.

9. Alterations in the Renin-Angiotensin System (RAS) and Gut Microbiome

• Mechanism: Persistent RAS dysregulation post-infection may underlie ongoing vascular, pulmonary, and metabolic symptoms[18]. Disturbed gut microbiome composition may also contribute to immune dysfunction and systemic inflammation[9][10].
• Evidence: Specific mechanistic links between RAS and long COVID symptomatology have been proposed but require further validation[18]. Gut microbiome abnormalities are reminiscent of those in other post-infectious syndromes.
• Therapeutic Implications: RAS modulators and microbiome-targeted therapies (e.g., probiotics) are being considered for investigation.

10. Post-COVID Organ Damage and New-Onset Disease

• Mechanism: Residual organ damage from acute infection may lead to chronic symptoms. Notably, new-onset diabetes has been observed in the post-acute phase, attributed to viral effects on pancreatic β-cells, persistent inflammation, and/or unmasking of pre-existing dysfunction[19].
• Therapeutic Implications: Screening for new organ dysfunction (e.g., diabetes, cardiovascular disease) is warranted, with management as per standard protocols.

Therapeutic Strategies: Leveraging Pathophysiological Insights

The complexity and heterogeneity of long COVID necessitate individualized, mechanism-based treatment approaches, ideally informed by clinical phenotyping and biomarkers[8][10][20]. Proposed strategies include:

• Antivirals for persistent viral reservoirs: Under investigation; may target a subset of patients with evidence of ongoing viral antigenic stimulation[2][3][5].
• Immunomodulation (corticosteroids, IL-6 inhibitors, low-dose naltrexone): Potential benefit in patients with biomarkers of chronic inflammation or immune dysregulation[14][6][8].
• Autoimmune therapies (B-cell depletion): Suitable for cases with clear autoimmune features, but broad use not substantiated by current evidence[12][8].
• Endothelial protection and anticoagulation: For those with microvascular symptoms or evidence of sustained endotheliopathy[13][6].
• Symptom-directed care: Rehabilitation, cognitive-behavioral interventions, neuropsychological support, and tailored autonomic management[15][14][17].
• Vaccination: Observational data indicate that vaccination may reduce long COVID risk post-infection and, for some, ameliorate established symptoms, possibly through modulation of immune responses or clearance of persistent antigen[21][22][5].

Conclusion

Long COVID arises from the complex interplay of persistent viral elements, dysregulated immunity (including chronic inflammation and autoimmunity), endothelial dysfunction, metabolic derangement, and sequelae of acute organ damage. Each mechanism offers a potential therapeutic target, but to date, no single intervention demonstrably reverses long COVID in all patients[5][8]. Future research should prioritize:

• Biomarker-based patient selection for trials,
• Stratification by clinical phenotype/mechanistic endotype,
• Multi-modality therapy combining antiviral, immunomodulatory, and symptom-specific approaches,
• Holistic rehabilitation, including management of neuropsychiatric and metabolic sequelae[20][8][10].

A precision medicine approach will be critical to effectively manage and, eventually, cure long COVID. Continued investment in mechanistic research and large-scale randomized clinical trials remains urgently needed[5][8][10].